Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study

Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Series:	RMD Open
Online Access:	https://rmdopen.bmj.com/content/11/1/e004476corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study
by: Hendrik Schulze-Koops, et al.
Published: (2024-10-01)

Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study
by: Arthur Kavanaugh, et al.
Published: (2025-01-01)

The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated with Filgotinib
by: Yoshiya Tanaka, et al.
Published: (2024-11-01)

Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
by: Jiangtao Li, et al.
Published: (2013-01-01)

Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
by: Gerd R Burmester, et al.
Published: (2019-10-01)

Long-Term Safety and Effectiveness of Canakinumab in Patients with MKD/HIDS: Interim Analysis of the RELIANCE Registry
by: Prasad T. Oommen, et al.
Published: (2024-12-01)

Leprosy—Presenting as Rheumatoid Arthritis Misleading the Correct Diagnosis
by: Dhakal Sagar, et al.
Published: (2025-01-01)

Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study
by: Tjalf Ziemssen, et al.
Published: (2025-02-01)

BOLOGNA PROCESS: EVOLUTION OF PRIORITIES AND INTERIM RESULTS
by: Gennady F. Tkach, et al.
Published: (2016-12-01)

Real-world assessment of effectiveness and safety of filgotinib in 286 patients with ulcerative colitis in 9 UK centres
by: David Young, et al.
Published: (2025-01-01)

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
by: Peter Nash, et al.
Published: (2020-10-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Efficacy of Abatacept for Arthritis in Patients with an Overlap Syndrome between Rheumatoid Arthritis and Systemic Lupus Erythematosus
by: Kei Ikeda, et al.
Published: (2013-01-01)

Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial
by: Philip J Mease, et al.
Published: (2018-08-01)

Adiponectin and rheumatoid arthritis
by: Beuy Joob, et al.
Published: (2019-01-01)

Interim results on concession agreements for the city of Perm and the Perm region
by: E. V. Rozhkov
Published: (2023-05-01)

Distinguishing rheumatoid arthritis from psoriatic arthritis
by: Joseph F Merola, et al.
Published: (2018-08-01)

Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis
by: Yuxuan Li, et al.
Published: (2019-01-01)

Impact of glucocorticoids on the therapeutic efficacy of denosumab against osteoporosis in patients with rheumatoid arthritis
by: Jiwon Yang, et al.
Published: (2025-01-01)

T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
by: Sonja Dulic, et al.
Published: (2017-01-01)

Cervical Myelopathy in Rheumatoid Arthritis
by: N. Mukerji, et al.
Published: (2011-01-01)

Long-term outcome of a treat-to-target strategy in late-onset rheumatoid arthritis with chronic lung disease: 5-year results of a prospective observational study
by: Manami Nomura, et al.
Published: (2025-02-01)

Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An extension study
by: Małgorzata Wisłowska
Published: (2024-11-01)

Tetracyclines in Rheumatoid Arthritis: Dual Anti-Inflammatory and Immunomodulatory Roles, Effectiveness, and Safety Insights
by: Mislav Radić, et al.
Published: (2025-01-01)

The Efficacy of Moxibustion on the Serum Levels of CXCL1 and β-EP in Patients with Rheumatoid Arthritis
by: Siyu Tao, et al.
Published: (2021-01-01)

Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension
by: Sofia Ramiro, et al.
Published: (2025-01-01)

Organizing Pneumonia Preceding Rheumatoid Arthritis
by: Yoshiaki Kinoshita, et al.
Published: (2014-01-01)

Main Ocular Manifestations in Rheumatoid Arthritis
by: Sandra Saray Quignon Santana, et al.
Published: (2009-12-01)

Geographic Socioeconomic Influences on Disease Activity in Rheumatoid Arthritis in an Academic and Safety Net Hospital System
by: Joseph Kim, et al.
Published: (2025-01-01)

No impact of seronegativity on the efficacy of a biosimilar rituximab in biologic-naïve patients with active rheumatoid arthritis
by: Nedumooli Pottammal Jamshid, et al.
Published: (2019-01-01)

Efficacy and safety of conventional synthetic, biologic, and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-interstitial lung disease: A narrative review
by: Richard Conway, et al.
Published: (2021-01-01)

Myostatin Levels and the Risk of Myopenia and Rheumatoid Cachexia in Women with Rheumatoid Arthritis
by: Fabiola Gonzalez-Ponce, et al.
Published: (2022-01-01)

Iatrogenic T-Cell Lymphoma with Associated Hemophagocytic Lymphohistiocyotsis in a Patient with Long-Standing Rheumatoid Arthritis
by: X. A. Andrade, et al.
Published: (2018-01-01)

Multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib in Behçet’s disease, idiopathic inflammatory myopathies and IgG4-related disease: DRIMID study protocol
by: Sander W Tas, et al.
Published: (2025-02-01)

Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”
by: Sang Jin Lee, et al.
Published: (2017-01-01)

The Use of Oral Analgesics and Pain Self-Efficacy Are Independent Predictors of the Quality of Life of Individuals with Rheumatoid Arthritis
by: Akira Hashimoto, et al.
Published: (2020-01-01)

Long-term antibody responses to COVAXIN and COVISHIELD vaccines in rheumatoid arthritis patients and healthy control population – A cross-sectional study
by: Vijaya Prasanna Parimi, et al.
Published: (2025-01-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis
by: Xavier Mariette, et al.
Published: (2022-02-01)

Treatment and Genotypic Characteristics of Patients with Rheumatoid Arthritis
by: Norbutoev Olimjon, et al.
Published: (2025-01-01)